728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

BioAmber Inc. Announces Pricing of US$10 Million Underwritten Public Offering

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

MONTREAL, Feb. 6, 2018 /PRNewswire/ – BioAmber Inc. (NYSE: BIOA) (TSX: BIOA) (“BioAmber” or the “Company”) announced today that it has priced an underwritten public offering of an aggregate of 40 million Series A units (or equivalent Series B Units), with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, and each Series B unit consisting of one pre-funded warrant to purchase one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, at a price to the public of US$0.25 per Series A unit and US$0.24 per Series B unit.

The Series A warrants have an exercise price of US$0.25 and a term of six (6) months, exercisable upon the date of issuance. The Series B warrants have an exercise price of US$0.25 and a term of five (5) years, exercisable upon the date of issuance. The pre-funded warrants have an exercise price of US$0.25 per share, which will be pre-paid upon issuance, except for a nominal exercise price of US$0.01 per share and, consequently, no additional payment or other consideration (other than the nominal exercise price of US$0.01 per share) will be required to be delivered to the Company by the holder upon exercise of the pre-funded warrants. The pre-funded warrants will be exercisable upon the date of issuance until exercised in full. The shares of common stock and the warrants will be immediately separable and will be issued separately.

The aggregate gross proceeds to the Company (assuming no exercise of the warrants) are approximately US$10 million, before deducting underwriting discounts and commissions and estimated offering expenses.

H.C. Wainwright & Co. is acting as the sole book-running manager in connection with this offering.

The closing of the offering is expected to occur on or about February 8, 2018, and is subject to customary closing conditions including, but not limited to, the receipt of all necessary approvals including the approval of the New York Stock Exchange (“NYSE”) and the Toronto Stock Exchange (“TSX”). The Company intends to use the net proceeds of the offering for working capital and general corporate purposes.

This press release shall not constitute an offer to sell, or

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *